JPRN-UMIN000016306
Completed
未知
The efficacy and safety of SGLT2 inhibitor for non alcholic fatty liver disease in Japanese patients with type 2 diabetes - SGLT2 inhibitor and NAFLD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Tokyo Medical and Dental University
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients treated with Sulphonyl urea, SGLT2 inhibitor, or insulin Patients with active infection, malignant disease, severe liver or renal dysfunction Pregnant women Patients with dementia or disturbance in consciousness
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Efficacy and safety in SGLT2 inhibitor for non-diabetes complicated by non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.JPRN-UMIN000031041Kobe university school of medicine, Diabetes and Endocrinoplogy30
Recruiting
Not Applicable
Efficacy and Safety of SGLT2 inhibitors in patients with type 1 diabete.JPRN-UMIN000044317Hokkaido University Hospital200
Completed
Not Applicable
ong-term efficacy and safety of the SGLT2 inhibitors in Japanese patients with type 2 diabetes mellitus.JPRN-UMIN000037872akakinen Clinic630
Recruiting
Phase 4
Efficacy of SGLT2 inhibitor for Non-Alcoholic Fatty Liver Diseaseon Alcoholic Fatty Liver DiseaseType 2 Diabetes MellitusObesityC06.552.241.519C18.452.394.750.149RBR-48rxwbCentro Educacional Hyarte
Completed
Not Applicable
Efficacy and Safety of SGLT-2 inhibitor to break loose from glucose toxicity and to withdraw insulin therapy in type 2 diabetic inpatientsJPRN-UMIN000013539Shiga University of Medical Science Department of Internal Medicine Division of Diabetology, Nephrology, Neurology20